Literature DB >> 10841992

Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects.

R Borghi1, R Marchese, A Negro, L Marinelli, G Forloni, D Zaccheo, G Abbruzzese, M Tabaton.   

Abstract

Several clues suggest that alpha-synuclein, a presynaptic protein, plays a central role in the pathogenesis of idiopathic Parkinson's disease (PD). To search a peripheral marker of PD, we analyzed presence and amount of alpha-synuclein in CSF from 12 PD patients and 10 neurologically normal subjects. The protein was extracted from CSF samples through immunoprecipitation and immunoblotting with different specific anti-alpha-synuclein antibodies. We identified a 19 kDa band that corresponds to monomeric alpha-synuclein, given its comigration with homologue human recombinant peptide as well as with the protein extracted from cerebral cortex of normal subjects. The amount of CSF 19 kDa alpha-synuclein did not significantly vary in PD and normal cases. These findings have two implications: (a) full length alpha-synuclein is released by neurons in the extracellular space; (b) alpha-synuclein does not appear a peripheral marker of PD pathology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10841992     DOI: 10.1016/s0304-3940(00)01153-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  139 in total

Review 1.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

2.  Identification of ciliary neurotrophic factor receptor alpha as a mediator of neurotoxicity induced by alpha-synuclein.

Authors:  Jun Liu; Min Shi; Zhen Hong; JianPeng Zhang; Joshua Bradner; Thomas Quinn; Richard P Beyer; Patrick L Mcgeer; ShengDi Chen; Jing Zhang
Journal:  Proteomics       Date:  2010-06       Impact factor: 3.984

3.  Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity.

Authors:  Karin M Danzer; Wolfgang P Ruf; Preeti Putcha; Daniel Joyner; Tadafumi Hashimoto; Charles Glabe; Bradley T Hyman; Pamela J McLean
Journal:  FASEB J       Date:  2010-09-27       Impact factor: 5.191

Review 4.  Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease.

Authors:  Seung-Jae Lee
Journal:  J Mol Neurosci       Date:  2007-04-17       Impact factor: 3.444

5.  Serological Analysis of Alpha-synuclein and NF-κB in Parkinson's Disease Patients.

Authors:  Vineeta Gupta; Ravindra Kumar Garg; Sanjay Khattri
Journal:  J Clin Diagn Res       Date:  2015-05-01

Review 6.  Cognitive impairment and dementia in patients with Parkinson disease.

Authors:  James B Leverenz; Joseph F Quinn; Cyrus Zabetian; Jing Zhang; Kathleen S Montine; Thomas J Montine
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

Review 7.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

8.  Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular α-synuclein in oligodendrocytes.

Authors:  Katharina Pukass; Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2013-11-12       Impact factor: 3.444

9.  Synthetic polyubiquitinated α-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology.

Authors:  Mahmood Haj-Yahya; Bruno Fauvet; Yifat Herman-Bachinsky; Mirva Hejjaoui; Sudhir N Bavikar; Subramanian Vedhanarayanan Karthikeyan; Aaron Ciechanover; Hilal A Lashuel; Ashraf Brik
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

10.  Detecting morphologically distinct oligomeric forms of alpha-synuclein.

Authors:  Sharareh Emadi; Srinath Kasturirangan; Min S Wang; Philip Schulz; Michael R Sierks
Journal:  J Biol Chem       Date:  2009-01-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.